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of people may have contracted
bird flu but were not diagnosed
because their symptoms were too
mild. The findings suggest some
populations have developed
natural resistance to the virus.
The study of more than 45,000
people in Vietnam, reveals that up
to 750 people are likely to have
become infected with the strain
after handling sick birds.
Anna Thorson, who led the
study, said the real figure
potentially extended into
thousands. The cases were not
picked up because, while people
developed coughs and a fever,
they either failed to seek medical
help because their symptoms
were mild, received treatment from
unregistered practitioners or were
missed by the doctors inspecting
them.
The researchers studied
interviews with more than 45,000
people in FilaBavi, a Vietnamese
demographic surveillance site with
confirmed outbreaks of H5N1 in
poultry during April to June 2004.
Eighty-four per cent lived in
households that kept poultry and
more than 25 per cent reported
birds falling ill or dying of flu in that
time. Of those between 650 and
750 people suffered flu-like
symptoms after handling the birds.
Although there are some
questions about the study and the
difficulty in diagnosing symptoms
in such a rural community, the
work has raised new issues
surrounding the virus.
The outbreak in Turkey has also
raised questions about the
apparent mildness of the virus in
some cases in this country. Part of
this may have been the result of
medical care which included the
administration of anti-viral drugs
such as Tamiflu but other
explanations for why the Turkish
death rate has been lower have
not been discounted. It could be,
for instance, that people in Turkey
are more resistant to the virus than
some of the Asian populations. Or
perhaps Turkish authorities were
able to detect cases more quickly.
Gene-sequencing information
can confirm where the victim
caught the disease — and so far
that seems in every case to be
from birds directly. “It’s not clear
yet that the situation we’re
observing in Turkey, the number of
infections, the virulence, is any
different than what we’ve been
seeing in Vietnam,” says the
MRC’s Alan Hay.
Professor Peter Dunhill, an
expert on vaccines for avian flu at
University College London, said
rural communities in Vietnam have
been living with bird flu for more
than 10 years and may have
developed resistance to it. “It may
well be that there is some
immunity in Turkey too.”
Recent developments in Turkey
and other countries on the eastern
edge of Europe have prompted
calls for the establishment of a
European task force that can be
mobilised to fight the virus.
Albert Osterhaus, a virologist at
the Erasmus Medical Centre in the
Netherlands and chairman of the
European scientific group on
influenza, believes more
coordination is needed in Europe
to tackle bird flu. 
“I think we should form a
European influenza task force that
brings together all our knowledge,
so that if you have outbreaks in
the future you could form
delegations to work together with
local experts in the area where it
occurs,” he told a meeting in
London last month.
But other researchers believe
the new findings and the current
pattern of bird flu, the human
infections and human influenza
may mean that a pandemic is still
some time away. While that may
give government authorities a little
more breathing space, there is
growing consensus that, if the
H5N1 strain leads to the next
human pandemic, the
consequences could be
catastrophic.
Writing recently, Neil Ferguson,
a specialist in infectious disease
epidemiology at Imperial College
London said: “the odds are that
there will be no human pandemic
in the next five years. However,
this is no reason for complacency
or a reduction in preparedness
planning. As the emergence of a
pandemic is, in essence, a chance
event, we cannot predict exactly
when the next pandemic will strike
or how severe its consequences
will be. That it will strike eventually
is certain.”
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A high profile delegation of UK researchers travelled to Havana last
month to discuss collaborative projects targeted at the life sciences.
Michael Gross reports.Cuban biotech has been growing
quietly but steadily over the last
two decades. It saw its most
spectacular success so far in July
2004, when the development of
the first ever fully synthetic
vaccine that is effective against a
human disease appeared in
Science magazine.
The synthetic vaccine against
Haemophilus influenzae B (HiB),
which was developed at the
Laboratory for Synthetic Antigens
at the University of Havana, is
much more affordable for
developing countries than the
biological vaccine available
previously (Curr. Biol. (2004) 14,
R401). As it could save the lives of
more than half a million children
per year, it made headlines around
the world. Since then, researchers
in other countries have becomeincreasingly interested in tapping
the Cuban expertise in fields such
as glycobiology, vaccine
development and immunology. 
Biologically oriented chemists
from leading UK universities
visited the Caribbean island to
experience the developments first
hand, to start new collaborations
and to consolidate existing ones.
The three-day binational
‘Symposium on Chemistry and
Life Sciences’ was held in
picturesque Old Havana. It was
co-chaired by Oxford chemistry
chairman Graham Richards and
Havana University’s Luis Montero
and backed by several UK
institutions, including the Royal
Society of Chemistry (RSC) and
Oxford University. 
As sugar is both a key resource
of the Cuban economy and a basis
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synthetic HiB vaccine, for example,
is a glycoconjugate),
glycosciences was one of the
scientific focus points of the
meeting.
Drug discovery, vaccine
development, and computational
methods were also covered.
Vicente Vérez, who led the
development of the HiB vaccine,
gave an account of this work and
a perspective on possible future
carbohydrate vaccines. “The
Havana meeting was a great
success,” said Graham Richards
after his return. Ben Davis, whose
group at Oxford develops new
approaches to glycoprotein and
glycoconjugate synthesis, said
that the meeting “was a great
scientific opportunity”.
Cuban participants in the
symposium were equally
enthusiastic about the event. “The
presentations of our UK
colleagues were outstanding,”
said Roberto Cao, the foreign
secretary of the Cuban chemical
society. Reynaldo Villalonga from
the University of Matanzas, who
collaborates with Ben Davis at
Oxford, agreed that “the meeting
was very successful and brought
mutual benefits”.Simultaneously with the
workshop, RSC president Simon
Campbell and board member
Rodney Townsend visited Havana
to explore in which ways the RSC
could get involved in collaboration
with Cuban researchers. They
signed a formal accord with the
Cuban Chemical Society
concerning the exchange of
information and materials.
After the symposium, the UK
delegates visited the laboratories
at the University of Havana and at
the Centre of Genetic Engineering
and Biotechnology (CIGB), one of
the leading research centres
clustered in the suburbs of the
Cuban capital. The CIGB was set
up in 1986 with the aim of
capitalising on the successful
production of recombinant
interferon in Cuba. Today it covers
a broad range of research fields. It
has developed successful
vaccines against hepatitis and tick
bites. We were impressed “with
the commitment to eradicate
infectious diseases,” said
Campbell.
The visitors also attended a
closing dinner together with
leading representatives of the
Cuban science administration,
including Fidel Castro’s sonFidel Jr., who acts as a scientific
advisor to his father. 
Participants from both countries
appear optimistic that the meeting
has advanced the potential of
collaborative life science efforts.
“It seems that some new
Cuba–UK collaborations will have
a starting point from this
workshop,” says Cao. 
Cuban biotech has a
remarkable position in that it
addresses typical Third World
problems, such as tropical
diseases, with research that
approaches First World
standards, thereby taking the lead
in some fields that have
enormous significance for global
health but have so far been all but
ignored by the pharmaceutical
giants. International collaboration
can help the cash-strapped
Cubans to develop their work
even further. With US researchers
still blocked by their own
government, scientists from
countries like Canada and the UK
can take the lead in helping to
realise the potential of Cuban
research. 
Michael Gross is a science writer based
at Oxford. He can be contacted via his
web page at www.proseandpassion.comCharm offensive: The glamour of Cuba is proving increasingly attractive to tourists but its growing bioscience reputation is also
proving a draw to leading researchers seeking new collaborations. (Photograph: Michael Gross.)
